Anti Inflammatory News and Research

RSS

SIRT1 gene appears to delay onset of HD in mouse model

Working with genetically engineered mice, Johns Hopkins researchers have discovered that a gene (SIRT1) linked to slowing the aging process in cells also appears to dramatically delay the onset of Huntington's disease (HD) and slow the progression of the relentless neurodegenerative disorder.

19 Dec 2011

Scientists identify how cells reduce tissue damage from inflammation in ALI model

Researchers at the University of Illinois at Chicago College of Medicine have found in an animal model of acute lung injury a molecular mechanism that allows cells of the immune system to reduce tissue damage from inflammation.

16 Dec 2011

Indiscriminate expensive imaging has little clinical benefit in patients requiring epidural steroid injections

Johns Hopkins-led research suggests that routine MRI imaging does nothing to improve the treatment of patients who need injections of steroids into their spinal columns to relieve pain. Moreover, MRI plays only a small role in a doctor's decision to give these epidural steroid injections (ESIs), the most common procedure performed at pain clinics in the United States.

14 Dec 2011

Scientists identify A2bAR as possible new therapeutic target against atherosclerosis

Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol.

13 Dec 2011

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

USPTO issues Diabetes Patent to Omni Bio

Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011. The Diabetes Patent expires in May 2022.

9 Dec 2011

Massive and consistent changes in inflammatory gene expression seen in trauma, burns

Serious traumatic injuries, including major burns, set off a "genomic storm" in human immune cells, altering around 80 percent of the cells' normal gene expression patterns. In a report to appear in the December Journal of Experimental Medicine, members of a nationwide research collaborative describe the initial results of their investigation into the immune system response to serious injury, findings which have overturned some longstanding assumptions.

8 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

INT-777 shows promise against metabolic syndrome

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation.

7 Dec 2011

White tea, witch hazel and rose have potential health and beauty properties

Age-old remedies could hold the key to treating a wide range of serious medical problems, as well as keeping skin firmer and less wrinkled, according to scientists from London's Kingston University.

2 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

MRG releases 2012 report on US markets for ENT and bronchoscopy devices

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, advances in procedures competing with functional endoscopic sinus surgery (FESS) and nasal packing devices will have a significant positive effect on the ear, nose and throat (ENT) device market in the United States over the next few years.

From Evident Corporation - Life Sciences 28 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Study examines how mice with genetic bone defects respond to infusions of BMMSC

A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.

21 Nov 2011

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."

19 Nov 2011

Dipyrone may reduce brain damage after stroke

An older nonsteroidal anti-inflammatory drug (NSAID) called dipyrone may offer a new approach to reducing injury to brain tissue after a stroke, according to a study in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Nov 2011

Cyanotech second quarter revenues increase to $5,989,000

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal year 2012, ended September 30, 2011.

14 Nov 2011